These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22795075)

  • 21. A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
    Klotz L; Schellhammer P; Carroll K
    BJU Int; 2004 Jun; 93(9):1177-82. PubMed ID: 15180600
    [No Abstract]   [Full Text] [Related]  

  • 22. Hormonal therapy for prostate cancer: past, present and future.
    el-Rayes BF; Hussain MH
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):37-47. PubMed ID: 12113064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
    Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
    BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
    Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
    J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermittent androgen deprivation: clinical experience and practical applications.
    Wright JL; Higano CS; Lin DW
    Urol Clin North Am; 2006 May; 33(2):167-79, vi. PubMed ID: 16631455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
    Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
    [No Abstract]   [Full Text] [Related]  

  • 27. Complete androgen blockade for prostate cancer: what went wrong?
    Laufer M; Denmeade SR; Sinibaldi VJ; Carducci MA; Eisenberger MA
    J Urol; 2000 Jul; 164(1):3-9. PubMed ID: 10840412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J
    Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 30. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
    Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary hormonal manipulations in prostate cancer.
    Ryan CJ; Small EJ
    Curr Oncol Rep; 2005 May; 7(3):228-33. PubMed ID: 15847715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controversies surrounding hormonal deprivation.
    Denis LJ
    Acta Urol Belg; 1996 May; 64(2):81-4. PubMed ID: 8701819
    [No Abstract]   [Full Text] [Related]  

  • 34. Secondary hormonal therapy for prostate cancer: what lies on the horizon?
    Sharifi N; Dahut WL; Figg WD
    BJU Int; 2008 Feb; 101(3):271-4. PubMed ID: 17922868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: Russell Szmulewitz, Supriya Mohile, Edwin Posadas, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009;56:97-104.
    Friedman AE
    Eur Urol; 2009 Nov; 56(5):e36; author reply e37. PubMed ID: 19683856
    [No Abstract]   [Full Text] [Related]  

  • 38. Secondary hormonal therapy.
    Smith DC
    Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J
    Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract]   [Full Text] [Related]  

  • 40. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.